July 25, 2013
2:30 pm to 3:30 pm EDT

Precision for Medicine

 

Symposium Course Description:

In a world where it is clear that healthcare costs must be contained, how can we afford to pay for innovation? This webinar will explore how personalizing treatment can offer an escape from the innovation-cost conundrum. By simultaneously increasing clinical development efficiency and the treatment effectiveness, targeting clinical innovations to the patients most likely to benefit can improve healthcare value per dollar spent while maintaining the ROI levels needed to support investment in innovation. We believe precision medicine should play a more prominent role in the cost containment discussion of healthcare reform.

Learning Objectives:

  • Help clients develop product development and commercialization strategies that get leverage from the benefits of precision medicine
  • Support positioning of innovations as part of the healthcare solution, not the problem
  • Understand and communicate the value proposition of precision medicine for payers, government decision makers, and legislators

Who Should Attend:


  • Franchise and Marketing Leaders
  • Therapeutic Area Leads
  • Medical Affairs
  • Government Affairs/Public Policy
  • Health Economics and Market Access

Program Agenda :


  • Is the high cost of healthcare innovation incompatible with control of healthcare costs?
  • Cost-effectiveness criteria and how they can be met
  • Taking cost out of clinical development
  • Case Example: How everyone can win
  • Practical impact on development and commercialization strategies
  • Q&A

David Parker, Ph.D.

Vice President, Market Access Strategy

Bethesda, MD

Dr. Parker has been active for more than 25 years in the healthcare industry, including 16 years of strategy consulting experience centered on the intersection of reimbursement, health economics, clinical science, and marketing strategy. He currently leads Precision for Medicine's Market Access consulting practice and provides strategic advisory services to the firm's biopharma, device, and diagnostics clients. His consulting encompasses all aspects of reimbursement, market access, and evidence development strategy with a particular focus on personalized medicine, molecular and advanced diagnostics, and medical devices.

Preceding his appointment at Precision, he led the Washington office of Boston Healthcare Associates. Before then, he was a senior consulting executive at Covance Market Access Services, where as a Vice President he led the Economic Strategies and Devices/Diagnostics practices. Prior to Covance, Dr. Parker was president of a biomedical consulting firm. Throughout his career, his work has resulted in numerous successful product launches, guided major investment and acquisition decisions, and driven favorable coverage and payment determinations by public and private payers alike.
His consulting career was preceded by eleven years of increasingly-responsible product and marketing management, strategic planning, and business development roles at biotechnology companies ranging from development-stage to units of Fortune 500 businesses. Early in his career, he conducted research in cell biology at Northwestern University Medical School.

Dr. Parker received a Ph.D. in Cell and Developmental Biology from the Massachusetts Institute of Technology, where he was a National Science Foundation Fellow, and an AB with high honors from Princeton University.

Vicki L. Seyfert-Margolis

Chief Scientific and Strategy Officer


Vicki L. Seyfert-Margolis, PhD joined Precision for Medicine in March 2013 as its Chief of Strategy and Science. In this role, she oversees scientific direction and strategy for development of science solutions to support precision medicine. This includes the assessment of new technologies, development of strategies for novel clinical trial designs, establishment of key academic and patient partnerships, and business development.

Prior to this, Dr. Seyfert-Margolis was the Senior Advisor of Science Innovation and Policy in the Office of the Commissioner of the U.S. Food and Drug Administration (FDA). While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science. Dr. Seyfert-Margolis was responsible for developing initiatives and programs to drive innovation both within the agency and industry, with a particular focus on moving personalized medicine and targeted therapeutic co-development pathways forward. She focused on agency wide big data initiatives, such as the creation of a scientific computing development environment, collaborations around large FDA datasets, and creation of a standardized repository for all FDA clinical data. She also served as the lead FDA representative on President Obama’s Council of Advisors of Science and Technology (PCAST) study “Propelling Innovation in Drug Discovery, Development and Evaluation”.

Previously, she served as Chief Scientific Officer at Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, Dr. Seyfert-Margolis oversaw the development of over 20 leading edge assay development and centralized laboratory facilities, bringing them to GLP and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases, including autoimmune disorders, allergy, and solid organ transplantation.

Dr. Seyfert-Margolis was also an Adjunct Associate Professor in the Department of Medicine at the University of California San Francisco. Prior to this, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases, where she worked to integrate emerging technologies into existing immunology and infectious disease programs.

Dr. Seyfert-Margolis completed her PhD in Immunology at the University of Pennsylvania’s School of Medicine.

Harry Glorikian

Managing Director, Strategy


Harry Glorikian joined Precision for Medicine as the Managing Director of Strategy and Personalized Medicine in December 2012 bringing world class advisory capabilities for life science and healthcare companies. Prior to Precision, Mr. Glorikian founded Scientia Advisors, a global management consulting firm specializing in strategy, operations, and pricing/reimbursement for major and emerging companies in healthcare, life sciences, pharma, biotechnology, and healthcare IT.

With 20 years of experience in the health care and life science industries, Mr. Glorikian has held senior management positions at Applied Bio Systems, Signet Laboratories, and X-Cell Laboratories, Inc. Mr. Glorikian has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology, and biodefense. His unique understanding of technologies, operations, and strategy from both customer and industry player perspectives has shaped a sophisticated framework and proprietary analytic tools.

Mr. Glorikian has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress, and other audiences worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, and many other media outlets.
Mr. Glorikian holds an MBA from Boston University and an undergraduate degree in Biology from San Francisco State University. He serves on many advisory boards and is an avid inventor who has several patents and patents pending in the U.S. and abroad.

Click here to access